Literature DB >> 2804053

Apolipoprotein E-1Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia.

W A Mann1, R E Gregg, D L Sprecher, H B Brewer.   

Abstract

Apolipoprotein E (apoE) is important in the modulation of the catabolism of chylomicron and very low density lipoprotein (VLDL) remnants. ApoE has three major genetically determined isoproteins in plasma, designated apoE-2, apoE-3 and apoE-4, with homozygosity for the allele coding for apoE-2 being associated with dysbetalipoproteinemia or type III hyperlipoproteinemia (HLP). We describe a new variant of apoE, apoE-1Harrisburg, which is, in contrast to apoE-2, dominantly associated with type III HLP. Five of twelve members of the affected kindred are heterozygous for the mutant form of apoE, and four of the five have type III HLP, while the fifth member has dysbetalipoproteinemia on diet therapy. Neuraminidase digestion, which removes charged sialic acid residues, did not alter the electrophoretic position of the apoE-1Harrisburg isoprotein, indicating that the altered charge of apoE-1Harrisburg was not due to sialic acid addition to the apolipoprotein. Cysteamine modification, which adds a positively charged group to cysteine, resulted in a shift of apoE-1Harrisburg from the E-1 to the E-2 isoform position, indicating that there is one cysteine in apoE-1Harrisburg as is the case for apoE-3. These results are consistent with apoE-1Harrisburg originating in the allele for apoE-3 with the mutation leading to a negative two-unit charge shift. The definitive identification of a kindred with an apoE variant, apoE-1Harrisburg, dominantly associated with dysbetalipoproteinemia and type III HLP provides a unique opportunity to gain important insights into the structure-function requirements of the E apolipoprotein as well as the mechanisms by which apoE modulates lipoprotein metabolism.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2804053     DOI: 10.1016/0005-2760(89)90043-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  11 in total

1.  Extracellular Interactions between Hepatitis C Virus and Secreted Apolipoprotein E.

Authors:  Zhihua Li; Yadong Li; Yanwei Bi; Hui Zhang; Yufeng Yao; Qihan Li; Wei Cun; Shaozhong Dong
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

2.  Effect of apolipoprotein E genotype on apolipoprotein B-100 metabolism in normolipidemic and hyperlipidemic subjects.

Authors:  Esther M M Ooi; Edward D Janus; Susan J Grant; Lucia M T Sinclair; P Hugh R Barrett
Journal:  J Lipid Res       Date:  2010-04-22       Impact factor: 5.922

Review 3.  Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk.

Authors:  Sebastiano Calandra; Patrizia Tarugi; Helen E Speedy; Andrew F Dean; Stefano Bertolini; Carol C Shoulders
Journal:  J Lipid Res       Date:  2011-08-23       Impact factor: 5.922

4.  Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia.

Authors:  A M van den Maagdenberg; W Weng; I H de Bruijn; P de Knijff; H Funke; A H Smelt; J A Gevers Leuven; F M van't Hooft; G Assmann; M H Hofker
Journal:  Am J Hum Genet       Date:  1993-05       Impact factor: 11.025

5.  Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency.

Authors:  K Ikewaki; D J Rader; T Sakamoto; M Nishiwaki; N Wakimoto; J R Schaefer; T Ishikawa; T Fairwell; L A Zech; H Nakamura
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

6.  Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.

Authors:  P de Knijff; A M van den Maagdenberg; D I Boomsma; A F Stalenhoef; A H Smelt; J J Kastelein; A D Marais; R R Frants; L M Havekes
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

7.  Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree.

Authors:  P de Knijff; A M van den Maagdenberg; A F Stalenhoef; J A Leuven; P N Demacker; L P Kuyt; R R Frants; L M Havekes
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

8.  Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu).

Authors:  W A Mann; P Lohse; R E Gregg; R Ronan; J M Hoeg; L A Zech; H B Brewer
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

9.  Biophysical analysis of apolipoprotein E3 variants linked with development of type III hyperlipoproteinemia.

Authors:  Dimitra Georgiadou; Angeliki Chroni; Alexander Vezeridis; Vassilis I Zannis; Efstratios Stratikos
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

Review 10.  Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis.

Authors:  Yun Chen; Michael R Strickland; Andrea Soranno; David M Holtzman
Journal:  Neuron       Date:  2020-11-10       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.